AN2 Therapeutics begins first-in-human trial of oral AN2-502998 for chagas disease

Phase 1 dosing is expected to finish by the end of 2025

Cohance to invest $10 million to expand cGMP bioconjugation capabilities in US

NJ Bio is currently executing a major new program for an existing innovator customer with multiple ADC candidates in their pipeline

Cohance Lifesciences appoints Yann D'Herve as CEO of CDMO Business

His experience includes leadership roles in manufacturing, strategic management, and commercial operations across the pharmaceuticals, healthcare, and specialty chemicals sectors

Godavari Biorefineries secures Chinese patent for anti-cancer molecule

Capricor receives FDA’s CRL for Deramiocel BLA for duchenne muscular dystrophy

Capricor’s BLA for Deramiocel received Priority Review in March 2025

Bemarituzumab Plus chemo improves overall survival in FGFR2b+ gastric cancer

New findings reveal bemarituzumab plus chemotherapy significantly improves survival in advanced gastric cancer, offering hope for targeted treatment options

Philogen withdraws marketing authorization application for Nidlegy in EU

The company's decision to withdraw the MAA was due to the timing of the availability of Chemistry Manufacturing and Controls

Dr. Lal PathLabs strengthens its genomics capabilities with Illumina's NovaSeq X Series

The NovaSeq X system features Illumina's cutting-edge XLEAP-SBS chemistry, offering unmatched throughput, accuracy, and sustainability

Remedium Lifecare secures Rs. 182.7 crore export deal

The CDMO upgrade represents a transformational step for Remedium Lifecare

Granules India bags EcoVadis’ Gold Rating

The company's first-ever corporate-level submission to EcoVadis builds on years of operational and environmental excellence